BMI View: Lithuania’s pharmaceutical and healthcare market represents a modest prospect for investment
from multinational firms. Increasing demand due to a rising burden of chronic disease will translate to an
increase in sales; however, fiscal policies and the small size of the market will limit revenue earning
opportunities.
Headline Expenditure Projections
? Pharmaceuticals: EUR616mn (USD677mn) in 2015 to EUR638mn (USD682mn) in 2016; +3.6% in
local currency terms and 0.7% in US dollar terms. Forecast unchanged from Q116.
? Healthcare: EUR2.15bn (USD2.37bn) in 2015 to EUR2.20bn (USD2.35bn) in 2016; +2.0% in local
currency terms and -0.8% in US dollar terms. Forecast unchanged from Q116.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Lithuania 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Lithuania 2012-2020) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2012-2020) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2012-2020) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2012-2020) 15
Prescription Drug Market Forecast 16
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Lithuania 2012-2020) 17
Patented Drug Market Forecast 18
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Lithuania 2012-2020) 19
Generic Drug Market Forecast 20
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Lithuania 2012-2020) 21
OTC Medicine Market Forecast 22
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Lithuania 2012-2020) 23
Pharmaceutical Trade Forecast 24
Table: Pharmaceutical Trade Data And Forecasts (Lithuania 2014-2020) 25
Table: Pharmaceutical Trade Data And Forecasts local currency (Lithuania 2014-2020) 26
Industry Risk Reward Index 27
Central And Eastern Europe Risk/Reward Index 27
Lithuania Risk/Reward Index 33
Rewards 33
Risks 33
Regulatory Review 35
Intellectual Property Regime 38
Pricing Regime 38
Table: Wholesale Mark-Ups For Reimbursed And Non-Reimbursed Medicines 39
Reimbursement Regime 40
Table: Retail Mark-Ups For Reimbursed And Non-Reimbursed Medicines 41
Market Overview 43
Healthcare Sector 44
Table: Healthcare Resources (Lithuania 2010-2015) 45
Table: Healthcare Personnel (Lithuania 2010-2015) 45
Table: Healthcare Activity (Lithuania 2010-2015) 46
Research & Development 47
Clinical Trials 49
Epidemiology 50
Competitive Landscape 53
Research-Based Industry 53
Table: Members of the Innovative Pharmaceutical Industry Association (IFPA) 53
Table: Multinational Market Activity 54
Generic Drugmakers 54
Pharmaceutical Distribution 55
Pharmaceutical Retail Sector 56
Company Profile 58
Valentis 58
Sanitas (Valeant) 60
Sicor Biotech (Teva) 63
Demographic Forecast 66
Table: Population Headline Indicators (Lithuania 1990-2025) 67
Table: Key Population Ratios (Lithuania 1990-2025) 67
Table: Urban/Rural Population & Life Expectancy (Lithuania 1990-2025) 68
Table: Population By Age Group (Lithuania 1990-2025) 68
Table: Population By Age Group % (Lithuania 1990-2025) 69
Glossary 71
Methodology 73
Pharmaceutical Expenditure Forecast Model 73
Healthcare Expenditure Forecast Model 73
Notes On Methodology 74
Risk/Reward Index Methodology 75
Index Overview 76
Table: Pharmaceutical Risk/Reward Index Indicators 76
Indicator Weightings 77

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Lithuania 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Lithuania 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2012-2020)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Lithuania 2012-2020)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Lithuania 2012-2020)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Lithuania 2012-2020)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Lithuania 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (Lithuania 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Lithuania 2014-2020)
Table: Wholesale Mark-Ups For Reimbursed And Non-Reimbursed Medicines
Table: Retail Mark-Ups For Reimbursed And Non-Reimbursed Medicines
Table: Healthcare Resources (Lithuania 2010-2015)
Table: Healthcare Personnel (Lithuania 2010-2015)
Table: Healthcare Activity (Lithuania 2010-2015)
Table: Members of the Innovative Pharmaceutical Industry Association (IFPA)
Table: Multinational Market Activity
Table: Population Headline Indicators (Lithuania 1990-2025)
Table: Key Population Ratios (Lithuania 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Lithuania 1990-2025)
Table: Population By Age Group (Lithuania 1990-2025)
Table: Population By Age Group % (Lithuania 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators